We are eager to advance the development of two very promising compounds for the treatment of bronchiectasis, Erdosteine and Doxofylline
Morristown, New Jersey (PRWEB) October 26, 2015
Alitair Pharmaceuticals, Inc., a clinical stage pharmaceutical company with multiple respiratory product candidates in development, announced today that it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by the Cleveland Clinic in Cleveland, Ohio, October 25 - 28, 2015. The purpose of the forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Alitair was selected to present based on its pipeline products’ potential for transformational impact on the orphan respiratory disease Bronchiectasis.
Michael Moffat, Cavendish co-founder and chief executive officer said, “The theme of our Cleveland Clinic-hosted forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that Is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of the Alitair Pharmaceuticals, Inc. approach to developing therapies for the orphan disease Bronchiectasis positions Alitair to make a major contribution to advancements in treatment for the 160,000 patients afflicted with this orphan disease in the U.S.”
“We are honored to have been selected to present at the upcoming Cavendish Global Health Impact Forum at the Cleveland Clinic,” said William W. Howard, president and CEO of Alitair. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and philanthropic individuals and families who share our dedication to improving the health and lives of people around the world.”
“Bronchiectasis is one of the country’s largest orphan diseases, and the annual medical costs for patients with Bronchiectasis are higher than many other chronic diseases, including heart disease and COPD,” continued Howard. “We are eager to advance the development of two very promising compounds for the treatment of Bronchiectasis, Erdosteine and Doxofylline. We regard presenting at the Cavendish Global Impact Forum as an opportunity to inspire others to join us in our work to address the significant unmet need for effective and safe Bronchiectasis therapies.”
Bronchiectasis is a condition in which the lungs produce excessive amounts of mucus. Cystic fibrosis is the best known disease that causes Bronchiectasis. In Bronchiectasis, the mucus builds up in the airways, allowing bacteria to grow, which leads to recurring infections. Each infection causes more damage to the airways, impairing the airways' ability to move air in and out of the lungs. Bronchiectasis can lead to serious health problems including respiratory failure, atelectasis, heart failure, and death.
About Alitair Pharmaceuticals
Alitair Pharmaceuticals, Inc., discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has two product candidates under development that have been granted orphan designations for the treatment of Bronchiectasis.
About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.